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Abstract
Introduction: Rheumatoid arthritis is an autoimmune arthritis in which two inflammatory cytokines, tumor necrosis
factor-α and interleukin-1β, play a critical role in the induction and progression of the disease. Several reports and
data from registries have discussed the association between chronic inflammatory diseases and disorders in
intermediary metabolism, pointing out that prevalence of peripheral insulin resistance and type 2 diabetes mellitus
is increased among patients with rheumatoid arthritis. In addition, several studies have shown that type 2 diabetes
mellitus may be considered an interleukin-1β inflammatory-mediated process, and both preclinical and clinical
observations have reported the usefulness of interleukin-1 antagonism therapy in this disease.
Case presentation: We describe the case of a 58-year-old Caucasian woman and a 74-year-old Caucasian man with
rheumatoid arthritis associated with type 2 diabetes mellitus. In these patients, the inhibition of interleukin-1β not
only induced remission for rheumatoid arthritis, but successfully controlled their metabolic status.
Conclusions: We report the positive effects of the inhibition of interleukin-1 in two patients with rheumatoid
arthritis associated with type 2 diabetes mellitus, with both reaching the therapeutic targets of their diseases by
using a single biological agent and tapering or discontinuing their antidiabetic therapies. These findings suggest
that targeting interleukin-1 might be considered a good therapeutic option for the treatment of rheumatoid
arthritis associated with type 2 diabetes mellitus.
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Introduction
Interleukin-1β (IL-1β) and tumor necrosis factor-α
(TNF-α) play a critical role in the induction and pro-
gression of rheumatoid arthritis (RA), and the efficacy of
therapies targeting these two inflammatory cytokines
confirms their prominent role in the disease [1]. Both
several reports and data from registries have suggested
that the prevalence of type 2 diabetes mellitus (T2DM)
is increased in patients with RA [2,3]. In addition, sev-
eral studies have shown that T2DM may be considered
an IL-1β inflammatory-mediated process, and both
preclinical and clinical observations have reported the
usefulness of IL-1 antagonism therapy in this disease
[4-6]. In this paper, we describe two patients with RA as-
sociated with T2DM, in which the inhibition of IL-1 in-
duced remission for RA and successfully controlled the
metabolic status, suggesting that targeting IL-1 might be
considered a good therapeutic option for the treatment
of RA associated with T2DM.
Case presentation
Case report one
A 58-year-old Caucasian woman was referred to our clinic
due to the insidious onset, in previous months, of arthral-
gias and arthritis. Her symptoms involved wrists, hands,
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shoulders and knees. She also reported notable morning
stiffness and fatigue, limiting her daily activities. The results
of her cardiological, pulmonary, dermatological, abdominal
and neurological examinations were unremarkable. In her
medical history, both essential hypertension and osteopor-
osis were reported. Laboratory findings showed an increase
of inflammatory markers and were negative for rheumatoid
factor (RF), antinuclear antibodies and anti-cyclic citrulli-
nated peptide (ACPA). A radiological examination of her
wrists and hands showed multiple bone erosions and juxta-
articular osteoporosis. Her Disease Activity Score in 28
Joints (DAS28), Simple Disease Activity Index (SDAI) score
and Patient Global Visual Analogue Scale (PG-VAS) score
were 4.5, 28 and 67mm, respectively, and active seronega-
tive RA was diagnosed. Combination therapy with metho-
trexate (15mg/weekly) (TEVA, Israel), hydroxychloroquine
(400mg/daily) (Sanofi, Italy) and a low dose of prednisone
(10mg/daily) (Bruno Farmaceutici, Italy) was prescribed.
She experienced a long clinical remission (her DAS28,
SDAI and PG-VAS scores were 2.2, 8.2 and 25mm, respect-
ively, after one year).
She experienced a new disease flare-up after two years,
characterized by multiple arthritis (wrists, hands and
knees) and an increase of morning stiffness and fatigue
(her DAS28, SDAI and PG-VAS scores were 5.2, 34.4
and 88mm, respectively). Infliximab (400mg/bi-monthly)
was introduced into her treatment regimen and a new
clinical remission was reached (her DAS28, SDAI and
PG-VAS scores were 2.4, 6.8 and 30mm, respectively)
for seven years. At this time, after her diagnosis of
T2DM (fasting plasma glucose (FPG) level 189mg/dL,
glycated hemoglobin (HbA1c) level 62mmol/mol, 7.8%
(4.8-5.9%)), she began taking a new oral hypoglycemic
drug (metformin 500mg trice/daily). One year later, fol-
lowing a new flare-up of her disease involving arthritis
of her wrists, hands, elbows, shoulders and knees (her
DAS28, SDAI and PG-VAS scores were 6.27, 34.6 and
80mm, respectively), her anti-TNF-α treatment with
infliximab (MSD, USA) was discontinued. Both her
methotrexate and steroids dosage remained stable; the
hydrossicloroquine was discontinued due to poor com-
pliance. Anakinra (Sobi, Sweden), a recombinant form of
a human IL-1 receptor antagonist, was introduced into
her therapy regimen (100mg/daily).
With regards to therapy for her T2DM, a stable dosage
of metformin was continued (FPG level 127mg/dL,
HbA1c level 60mmol/mol, 7.6%). In the six subsequent
months a new clinical remission was observed. After
three months of therapy, her DAS28, SDAI and PG-VAS
scores were 3.88, 24.2 and 74mm, respectively. At the
same time, her FPG and HbA1c levels were 108mg/dL
and 46mmol/mol, 6.3%, respectively. After six months of
therapy, her DAS28, SDAI and PG-VAS scores were
2.52, 9.2 and 30mm, respectively. Furthermore, repeated
tests showed a stable further reduction in her FPG and
HbA1c levels at 103mg/dL and 46mmol/mol (6.3%) (4.8-
5.9%), respectively. In Figure 1, the values of DAS28,
SDAI, PG-VAS, inflammatory markers, FPG and HbA1c
are reported. A reduction of daily intake of metformin
was observed (metformin 500mg once/daily). Fasting in-
sulin levels were increased following treatment with ana-
kinra: 34pmoles/liter at baseline; 43 pmoles/liter at three
months and 69pmoles/liter at six months, respectively.
Similarly, we observed that fasting C-peptide levels were
increased: 0.4nmoles/liter at baseline; 0.6nmoles/liter at
three months and 0.8nmoles/liter at six months, respect-
ively. During the follow-up period, her weight, frequency
of physical exercise and diet/caloric intake did not mod-
ify. No side effects were observed.
Case report two
A 74-year-old Caucasian man with an eight-year history of
RA, treated by a combination therapy with methotrexate
(15mg/weekly), hydroxychloroquine (200mg/daily) and
methylprednisolone (Pfizer, Italy) (16mg/daily at the be-
ginning, progressively tapered to 3 to 4mg/daily), obtain-
ing a stable and sustained good clinical response (DAS28
not available) was admitted to our unit with a new flare-
up of the disease consisting of multiple swelling joints,
mainly involving his hands and feet, with a symmetrical
pattern. He showed DAS28, SDAI and PG-VAS scores
of 3.78, 11.5 and 51mm, respectively. In addition, screening
for autoimmunity highlighted positivity for RF (100UI/mL)
and ACPA (1326UI/mL). He also reported a history of un-
controlled T2DM in the last 12 months, treated with repa-
glinide 0.5mg twice daily (Novo Nordisk Farmaceutici,
Italy) (FPG level 310mg/dL, HbA1c level 73mmol/mol,
8.8% (4.8-5.9%)) despite the lower levels of methylpredniso-
lone (3 to 4mg/daily) (Pfizer, Italy) employed. Anakinra
(100mg/daily subcutaneously) (Sobi, Sweden) was started,
in addition to methotrexate (10mg/weekly) (TEVA, Israel)
and methylprednisolone (3-4mg daily) (Pfizer, Italy), leading
to clinical improvement within a few days.
At his three-month follow-up, his DAS28, SDAI and
PG-VAS scores had dropped to 1.53, 3.3 and 22mm, re-
spectively. In addition, although oral anti-diabetic therapy
was tapered off eight days after anakinra introduction due
to a poor compliance, an improvement in glycemic con-
trol was noted (his FPG and HbA1c levels were 96mg/dL
and 54mmol/mol, 7.1% (4.8-5.9%), respectively). At six
months his DAS28, SDAI and PG-VAS scores were 1.89,
6.7 and 20mm, respectively, and a further improvement of
both his FPG and HbA1c levels was observed (92mg/dL
and 45.36mmol/mol, 6.3% (4.8-5.9%), respectively). His
fasting insulin level was increased following treatment
with anakinra: 36pmoles/liter at baseline, 53pmoles/liter
at three months and 77pmoles/liter at six months, re-
spectively. Similarly, we observed that his fasting C-
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peptide levels were increased: 0.6nmoles/liter at baseline,
1.1nmoles/liter at three months and 1.5nmoles/liter at six
months, respectively. His weight, frequency of physical ex-
ercise and diet/caloric intake did not modify during the
follow-up. No side effects were observed.
Discussion
We show that anakinra, prescribed for the treatment of
relapsing RA in two rheumatic patients with associated
T2DM, controls not only the clinical pictures of RA, but
also their metabolic status, confirming previous reports
suggesting that IL-1 blockade may be helpful in patients
with T2DM and inflammatory rheumatic diseases [7].
In both case studies, our patients reached a sustained
DAS28 remission after introduction of anakinra, without
any side effects observed during the follow-up periods.
IL-1β is highly expressed in RA, promoting activation of
leukocytes, endothelial cells, chondrocytes and osteoclasts
[1], and targeting IL-1 reduces inflammation, joint damage
and slows the radiographic progression in patients with
RA [8]. Moreover, no opportunistic infections in treated
patients have been reported [8].
Diabetes mellitus is a chronic disease due to a failure
in both producing and using insulin. When compared
with healthy people, patients with T2DM display a two-
four-fold increased risk of coronary artery disease [2,3].
On the other hand, it is well known that RA is an inde-
pendent risk for cardiovascular disease (CVD), and at
present, cardiovascular (CV) events are the leading cause
of death in patients with RA [2,3,9]. A prospective longi-
tudinal large cohort study showed that traditional CV
risk factors and markers of RA severity might both con-
tribute in predicting fatal CV events [10]. On this basis,
our patients (with both RA and T2DM) displayed a
much higher risk of CVD and related mortality.
Figure 1 Clinical charateristics of evaluated patients during six months of follow-up. Disease Activity Score in 28 Joints (DAS28) (a), Simple Dis-
ease Activity Index (SDAI) (b), Patient Global Visual Analogue Scale (PG-VAS) (c), erythrocyte sedimentation rate (ESR) (d), C-reactive protein values
(CRP) (e), body weight (f), fasting plasma glucose (g) and glycosylated hemoglobin (h) concentrations in our two patients at the beginning of
anakinra treatment and after three and six months of follow-up.
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In our patients, we observed that anakinra adminis-
tered to treat RA controlled their metabolic disorder. A
significant reduction of both FPG and HbA1c levels was
observed. It is well known that the pharmacologic inter-
ventions for T2DM are aimed at improving both FPG
and HbA1c levels, as suggested by the American Dia-
betes Association and the American Association of Clin-
ical Endocrinologists [11]. Large clinical trials have shown
that intensive treatments are associated with a significant
decrease of CV events [5,11]. It must be pointed out that
by treating our patients with an anti-IL-1 agent, we were
able to reach the optimal therapeutic targets for both RA
and T2DM, thus decreasing their CVD risk according to
the European League Against Rheumatism recommenda-
tions [9]. These results may suggest new therapeutic pos-
sibilities in patients with both RA and T2DM.
It must be pointed out that when diabetic patients are
treated with oral antidiabetic drug monotherapy, after an
initial improvement, a progressive and inexorable de-
cline in β-cell function may be observed. Many studies
showed that after three years of treatment, the disease
may be controlled by monotherapy in only 50%, and in
only 25% after nine years [11], confirming that T2DM is
a progressive disease and combined therapies are needed
to achieve and maintain metabolic targets [4,5,11]. In
our study, one patient decreased her daily antidiabetic
drug intake, while the other patient discontinued the
specific antidiabetic therapy. In this setting, anakinra
was able to determine both a stable DAS28 remission
and a glycemic control after six months and that an
anti-IL-1 therapy allowed our patients to control their
rheumatic disease without increasing steroid treatment,
associated with an increased risk of CV events, in a
dose-related manner [12].
Taken together, these results support that IL-1 antag-
onism may be a specific therapy in RA with associated
T2DM. Although the role of IL-1β has been extensively
studied in RA, recently several studies have suggested
this cytokine as a key cytokine in the pathogenesis of
T2DM [4,5]. In fact, under the influence of higher gly-
cemic levels, islets macrophages start to produce inflam-
matory cytokines, including IL-1β and TNF-α, which
increase the β-cell apoptosis rate, thus contributing to
the impairment in pancreatic secretory function [4,5].
In this setting, Larsen et al. performed a double blind,
parallel-group trial, involving 70 T2DM patients ran-
domly assigned to receive 100mg of anakinra or placebo.
At 13 weeks, the anakinra group showed an improve-
ment of HbA1c levels, the C-peptide secretion was en-
hanced and a reduction in the ratio of proinsulin to
insulin and in levels of IL-6 and C-reactive protein
(CRP) was observed [6]. Furthermore, the extension of
this study showed that this improvement lasted at least
39 weeks after treatment withdrawal [13]. In our
patients, we observed a reduction of HbA1c and CRP
levels associated with an increase of insulin levels and
C-peptide, mirroring what was already observed in the
study by Larsen et al., and suggesting an improvement
of β-cell function. In this context, it has been recently
shown that anakinra is able to increase insulin secretion
[14], and this insulin availability may explain its meta-
bolic effects.
Recently, Moran et al. reported that anakinra therapy
was not effective in type 1 diabetes (T1DM) patients
[15]. It must be pointed out that the insulitis in T1DM
is mainly driven by an autoimmune-mediated process
rather than an autoinflammatory process as observed in
T2DM, and this different mechanism suggests that IL-1
blockade may not be considered a good strategy to in-
hibit the pathogenesis of T1DM [5,15].
Conclusions
In conclusion, we report the positive effects of anakinra
for two patients with RA associated with T2DM reach-
ing the therapeutic targets of both the diseases, using a
single biological agent, and allowing us to taper or dis-
continue their antidiabetic therapies. In this setting, fur-
ther specifically designed studies must be performed to
evaluate the safety and long-term efficacy of anakinra in
patients with RA associated with T2DM, and the subse-
quent reduction of CV events in this population. On these
bases, an open, randomized, controlled, double-arm,
multi-center study, whose primary endpoint is the efficacy
of anakinra in controlling the signs and symptoms of
T2DM in patients with RA affected by this metabolic dis-
order, is actually ongoing in our country (TRACK study,
Clincaltrials.gov identifier: NCT02236481).
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